AVELOX I.V. Rx
Generic Name and Formulations:
Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free.
Indications for AVELOX I.V.:
Susceptible infections including acute bacterial sinusitis (ABS), acute bacterial exacerbations of chronic bronchitis (ABECB), community acquired pneumonia, skin and skin structure, complicated intra-abdominal infections, plague. For ABS and ABECB: reserve for those who have no alternative treatment options.
≥18yrs: 400mg once daily. ABS: treat for 10 days. ABECB: treat for 5 days. Pneumonia: treat for 7–14 days. Skin and skin structure: treat for 7 days, if complicated: 7–21 days. Intra-abdominal: treat for 5–14 days. Plague: treat for 10–14 days; begin as soon as possible after suspected or confirmed exposure. IV formulation may be used if oral route not preferable; administer IV infusion over 60 mins, may switch from IV to oral route when clinically indicated.
<18yrs: not established.
Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS effects); discontinue immediately if signs/symptoms occur. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. History of myasthenia gravis; avoid. History of QT prolongation, ventricular arrhythmias, proarrhythmic conditions (eg, bradycardia, acute myocardial ischemia), hypokalemia, or hypomagnesemia; avoid. Do not exceed recommended dose or infusion rate; may increase QT prolongation. Hepatic impairment. Monitor ECG in liver cirrhosis. Discontinue at 1st sign of a skin rash, jaundice, or any other hypersensitivity. Monitor blood glucose in diabetic patients; discontinue if hypoglycemia occurs. Maintain adequate hydration. Avoid excessive sun or UV light. Elderly. Pregnancy: avoid. Nursing mothers: not recommended.
Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, cisapride, erythromycin, antipsychotics, tricyclics). Oral forms: take at least 4hrs before or 8hrs after iron, zinc, magnesium, aluminum, sucralfate, didanosine (buffered forms). Increased risk of tendinitis/tendon rupture with corticosteroids. Monitor warfarin. Concomitant antidiabetics may cause blood glucose disturbances. Concomitant NSAIDs may increase seizure risk.
Nausea, diarrhea, dizziness, headache, convulsions, other CNS effects, abdominal pain, inj site reaction; hypersensitivity reactions, abnormal liver function tests, rash, phototoxicity (discontinue if occurs), tendinitis/tendon rupture, peripheral neuropathy, C. difficile-associated diarrhea.
Tabs—30; ABC Pack (5 tabs)—1; Premixed IV soln (250mL)—1
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored